Novo Nordisk Concludes Up to $5.2 Billion Takeover of Akero Therapeutics

09:38 AM EST, 12/09/2025 (MT Newswires) -- Danish drugmaker Novo Nordisk (NOVO-B.CO) said Tuesday it completed its purchase of US-based clinical-stage company Akero Therapeutics. As a result of the closing, Akero's shares will be delisted from the Nasdaq Global Select Market. Novo Nordisk announced the up to $5.2 billion deal on Oct. 9. It will pay $54 for each Akero share, plus a contingent value right of $6 per share upon US regulatory approval for Akero's efruxifermin to treat compensated cirrhosis.